ATE264618T1 - Behandlung von durch vielfach ungesättigten lipid-metaboliten vermittelten lungenerkrankungen und tests für epoxidhydrolase-inhibitoren - Google Patents

Behandlung von durch vielfach ungesättigten lipid-metaboliten vermittelten lungenerkrankungen und tests für epoxidhydrolase-inhibitoren

Info

Publication number
ATE264618T1
ATE264618T1 AT97938335T AT97938335T ATE264618T1 AT E264618 T1 ATE264618 T1 AT E264618T1 AT 97938335 T AT97938335 T AT 97938335T AT 97938335 T AT97938335 T AT 97938335T AT E264618 T1 ATE264618 T1 AT E264618T1
Authority
AT
Austria
Prior art keywords
testing
treatment
lung disease
disease mediated
hydrolase inhibitors
Prior art date
Application number
AT97938335T
Other languages
English (en)
Inventor
Bruce D Hammock
Mehran F Moghaddam
Jeffrey M Cheek
Babak Borhan
James Fergusson
David F Grant
Jessica F Greene
Kazu Matoba
Jiang Zheng
Marlene F Sisemore
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE264618T1 publication Critical patent/ATE264618T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97938335T 1996-08-13 1997-08-13 Behandlung von durch vielfach ungesättigten lipid-metaboliten vermittelten lungenerkrankungen und tests für epoxidhydrolase-inhibitoren ATE264618T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2339796P 1996-08-13 1996-08-13
US08/909,523 US5955496A (en) 1996-08-13 1997-08-12 Dihydroxy-oxy-eicosadienoates
PCT/US1997/014385 WO1998006261A1 (en) 1996-08-13 1997-08-13 Methods of treating pulmonary diseases mediated by polyunsaturated lipid metabolites and assays for epoxide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
ATE264618T1 true ATE264618T1 (de) 2004-05-15

Family

ID=26697082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938335T ATE264618T1 (de) 1996-08-13 1997-08-13 Behandlung von durch vielfach ungesättigten lipid-metaboliten vermittelten lungenerkrankungen und tests für epoxidhydrolase-inhibitoren

Country Status (8)

Country Link
US (1) US5955496A (de)
EP (1) EP0926951B1 (de)
AT (1) ATE264618T1 (de)
AU (1) AU4069297A (de)
CA (1) CA2262525C (de)
DE (1) DE69728776T2 (de)
ES (1) ES2221064T3 (de)
WO (1) WO1998006261A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693130B2 (en) * 1999-02-18 2004-02-17 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19847778A1 (de) * 1998-10-16 2000-04-20 Basf Ag Verfahren zur Herstellung von substituierten Dibenzoylmethanverbindungen
WO2000023060A2 (en) * 1998-10-20 2000-04-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by t-lymphocytes
US6916843B1 (en) 1999-08-11 2005-07-12 The United States Of America As Represented By The Department Of Health And Human Services Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2002082082A2 (en) * 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
US6979733B2 (en) * 2001-08-03 2005-12-27 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050026844A1 (en) * 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US20050222252A1 (en) * 2004-03-31 2005-10-06 The Regents Of The University Of California Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
JP2008517072A (ja) 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US20060276515A1 (en) * 2005-05-06 2006-12-07 Cywin Charles L Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
WO2006121684A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Acyl hydrazones for treating cardiovascular diseases
US8242170B2 (en) 2005-06-06 2012-08-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
CA2619768A1 (en) * 2005-08-19 2007-02-22 The Regents Of The University Of California Use of seh inhibitors as analgesics
JP2009511489A (ja) * 2005-10-07 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益なｎ−置換ピリジノン又はピリミジノン化合物
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
US8263651B2 (en) * 2006-12-15 2012-09-11 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors
CN101563088A (zh) * 2006-12-18 2009-10-21 弗·哈夫曼-拉罗切有限公司 可溶性环氧化物水解酶的抑制剂的新用途
WO2008103753A2 (en) * 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US8455520B2 (en) * 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
EP2135516B1 (de) 2008-06-13 2012-08-15 Symrise AG Neo-Menthylderivate als Geschmacksstoffe
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US20160008342A1 (en) 2014-06-16 2016-01-14 The Regents Of The University Of California Methods of improving cell-based therapy
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
EP3463470A1 (de) 2016-05-25 2019-04-10 Johann Wolfgang Goethe-Universität Frankfurt am Main Behandlung und diagnose von nichtproliferativer diabetischer retinopathie
WO2020074549A1 (en) 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088779A (en) * 1973-05-18 1978-05-09 Ciba-Geigy Corporation 9-Oxaprostaglandins
EP0360246B1 (de) * 1988-09-21 1994-03-30 G.D. Searle & Co. 3-Oxiranbenzoesäuren und Derivate
US5488033A (en) * 1989-07-28 1996-01-30 The Regents Of The University Of California Treatment to reduce edema
JP2635212B2 (ja) * 1990-04-30 1997-07-30 アイシス・ファーマシューティカルス・インコーポレーテッド アラキドン酸代謝のオリゴヌクレオチド変調
US5455271A (en) * 1992-06-18 1995-10-03 The Scripps Research Institute Tight-binding inhibitors of leukotriene A4 hydrolase
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5503990A (en) * 1994-11-09 1996-04-02 Kurth; Gerhard D. Preparation of health food supplement product
US5504111A (en) * 1994-12-30 1996-04-02 Medichem Research, Inc. Use of 2,3 alkylcarbonyloxybenzoic acid in treating adult respiratory distress syndrome

Also Published As

Publication number Publication date
DE69728776D1 (de) 2004-05-27
AU4069297A (en) 1998-03-06
CA2262525A1 (en) 1998-02-19
DE69728776T2 (de) 2005-05-25
EP0926951B1 (de) 2004-04-21
EP0926951A1 (de) 1999-07-07
WO1998006261A1 (en) 1998-02-19
CA2262525C (en) 2011-05-03
EP0926951A4 (de) 2001-08-08
ES2221064T3 (es) 2004-12-16
US5955496A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
ATE264618T1 (de) Behandlung von durch vielfach ungesättigten lipid-metaboliten vermittelten lungenerkrankungen und tests für epoxidhydrolase-inhibitoren
ATE360989T1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69620161D1 (de) Thrombininhibitoren
DE69528528D1 (de) Thrombin-inhibitoren
DE69423436D1 (de) An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
DE69904079D1 (de) Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
DE60239009D1 (de) Testmethode zum auffinden von potentiellen medikamenten zur behandlung von entzündungskrankheiten
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
NO851225L (no) Sammensetning og forsoeksinnretning til bestemmelse av tilstedevaerelsen av leukocytter, esterase og protease i en proeve
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE279919T1 (de) Agmatin für die behandlung neuropathischer schmerzen
DE69618820D1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DE60012140D1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE61051T1 (de) Substituierte pyrimidinamide von oelsaeure oder linolsaeure als inhibitoren von acyl-coa cholesterin-acyltransferase.
WO2003105753A3 (en) METHODS AND COMPOSITIONS FOR GRAFTING FUNCTIONAL LOOPS INTO A PROTEIN
ATE187461T1 (de) Cyklopeptolide
EA200000522A1 (ru) 5-htагонисты
DE69934325D1 (de) Zusammenstellungen zur erhöhung der darmabsoption von fetten
ATE377760T1 (de) Verfahren zum auffinden von verbindungen, die der vorsorge gegen cardiovasculäre krankheiten dienen
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest
DE69626860D1 (de) Elisa testsystem zur bestimmung von substanzen, die die bindung zwischen ig e und dessen receptor inhibiert

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties